IL-PRICEFX
14.5.2020 15:32:04 CEST | Business Wire | Press release
Pricefx , the global leader in native cloud pricing software, today introduced Lightning , the first turnkey solution to enable rapid activation of pricing excellence. Powered by Pricefx Accelerators, Lightning delivers a full suite of standard pricing analytics, management and CPQ realization tools, able to go live in six weeks or less. Customers can accelerate their Pricefx implementation with fast, easy to deploy, pre-configured pricing capabilities.
Businesses are increasingly considering pricing software as a way to navigate the current economic climate. Yet when trying to improve their enterprise pricing approach, customers can face a steep climb to reach activation.
“In my experience, it’s not uncommon for companies to struggle getting started with pricing software,” said Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Starting with a blank whiteboard and getting all stakeholders to agree on the strategy, rules, fundamental approaches and a budget can derail a project before it gets off the ground. With Lightning, Pricefx is attempting to address these challenges by offering pre-configured pricing capabilities out of the box. Using a point-click-deploy approach, Pricefx Lightning is designed to significantly reduce the barriers to adopting a full scope pricing solution.”
Pricefx Lightning offers industry standard, pre-configured foundations for analytics dashboards, pre-defined yet flexible pricing strategies, and instant communication to the field. Removing the friction from implementing a full scope pricing solution, Pricefx offers a point-click-deploy approach designed to empower users who only need to add data to get started. This allows organizations to start the process from the halfway point, skipping weeks or months working through initial configurations.
Once up and running, Pricefx enables users to refine and customize focused on their specific business needs, removing costly proof of concept cycles spent on defining basic requirements. Powered by Pricefx PriceAnalyzer and Sales Insights Accelerator, Lightning provides a powerful pre-configured data analytics environment of out-of-the-box dashboards with more than a dozen optional additional configurations. To gain pricing insights, users simply load their data and start seeing new opportunities for growth and improvement.
To activate analytics-powered insights, Pricefx Lightning provides a robust price setting and management capability connected directly into the customer’s analytics, making the implementation of new intelligence seamless and instant. The analytics and management are natively integrated into the platform, which allows the strategy to be delivered to the field organization in real time. Pricefx pricing platform uses a full featured CPQ including standard workflows, in-line approvals, chat and e-signature support, removing any barriers to delivering pricing excellence.
“Lightning is a first-of-its-kind, tech-enabled fast lane for pricing excellence, designed to supercharge your implementation without breaking the bank,” said Marcin Cichon, CEO and co-founder at Pricefx. “At the outset of this initiative, our goal was to skip the POC stage and get customers working with a live product. We believe that by delivering out-of-the-gate value Pricefx can provide an informed launch point that enables businesses to focus on enhancements that create a competitive advantage and build organizational alignment with real data and results. With Lightning, we can dramatically accelerate time-to-value and have customers running live in six weeks – no one else on the market can deliver that.”
Lightning is the result of 18 months of work, with dozens of customers in more than 10 vertical industries. Its broad, versatile and flexible standard set of pre-configurations are designed to meet the analytics, management and realization needs of any organization looking to rapidly improve their entire pricing capability.
Lightning is free to activate through June 2020 with a signed subscription agreement for the three modules that power the solution – PriceAnalyzer , PriceBuilder and QuoteConfigurator . Interested customers should contact their current Pricefx representative for more information .
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005236/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom